Literature DB >> 1845963

Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane.

F Tesson1, C Prip-Buus, A Lemoine, J P Pegorier, A Parini.   

Abstract

Imidazoline-guanidinium-receptive site (IGRS) is a membrane protein that, even if recognized by a series of imidazoline and guanidinium alpha 2-adrenergic compounds, is insensitive to catecholamine and physically distinct from alpha 2 receptors (Parini, A., Coupry, I., Graham, R. M., Uzielli, I., Atlas, D., and Lanier, S. M. (1989) J. Biol. Chem. 264, 11874-11878). In the present report, we defined the subcellular localization of IGRS by performing binding studies with the imidazoline radioligand [3H]idazoxan. Binding studies on subcellular fractions of homogenates from human and rabbit liver showed a significant increase in [3H]idazoxan binding in a membrane fraction enriched in cytochrome oxidase activity, a specific marker for mitochondria. The enrichment in [3H]idazoxan binding sites correlates closely with cytochrome oxidase activity in the nuclear, mitochondrial, plasma membrane, microsomal, and soluble fractions (r = 0.966, p less than 0.002) but not with the specific markers for other cell compartments, suggesting a major localization of IGRS in mitochondria. Separation of inner and outer mitochondrial membranes by digitonin treatment showed that [3H]idazoxan binding correlates positively with monoamine oxidase (r = 0.960) and negatively with cytochrome oxidase (r = -0.950) activities. In addition, in highly purified preparations of outer mitochondrial membranes obtained by hypotonic shock, [3H]idazoxan binding activity was 12.5-fold enriched with respect to intact mitochondria. Taken together, these data show, for the first time, that IGRS in human and rabbit liver are mainly associated with the outer mitochondrial membranes. This demonstration of the major mitochondrial localization of IGRS will facilitate the characterization of its functional activity in liver.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845963

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 2.  Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?

Authors:  Andrew Holt
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

3.  Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor.

Authors:  G Olmos; N DeGregorio-Rocasolano; M Paz Regalado; T Gasull; M Assumpció Boronat; R Trullas; A Villarroel; J Lerma; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 4.  The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.

Authors:  P Ernsberger; J E Friedman; R J Koletsky
Journal:  J Hypertens Suppl       Date:  1997-01

5.  The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain.

Authors:  G Olmos; R Alemany; P V Escriba; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Contrasting effects of the imidazol(in)e alpha 2-adrenoceptor agonists, medetomidine, clonidine and UK 14,304 on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialysis and synaptosomal uptake studies.

Authors:  J W Dalley; S C Stanford
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: pharmacological characterization and relationship to monoamine oxidase.

Authors:  A Renouard; P S Widdowson; A Cordi
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

8.  Interaction of inactivated and active ribulose 1,5-bisphosphate carboxylase/oxygenase of Rhodobacter sphaeroides with nucleotides and the chaperonin 60 (GroEL) protein.

Authors:  X Wang; F R Tabita
Journal:  J Bacteriol       Date:  1992-06       Impact factor: 3.490

9.  Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.

Authors:  N J Mallard; A L Hudson; D J Nutt
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

10.  Antineoplastic activity of idazoxan hydrochloride.

Authors:  G F Eilon; L Weisenthal; M Stupecky; G Landucci; L M Slater
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-24       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.